Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Myriad: Q4 Earnings Snapshot AP - Tue Feb 27, 4:26PM CST

Myriad: Q4 Earnings Snapshot

MYGN : 19.97 (+2.57%)
Myriad: Q3 Earnings Snapshot AP - Mon Nov 6, 2023

Myriad: Q3 Earnings Snapshot

MYGN : 19.97 (+2.57%)
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research PR Newswire - Fri Oct 20, 2023

/PRNewswire/ -- USA News Group - According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic...

ONC.TO : 1.61 (+0.62%)
BNTX : 93.35 (+0.68%)
ONCY : 1.1800 (+0.85%)
SGEN : 228.74 (-0.07%)
MYGN : 19.97 (+2.57%)
ILMN : 118.98 (+0.89%)
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research FinancialNewsMedia - Fri Oct 20, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END

ONCY : 1.1800 (+0.85%)
ONC.TO : 1.61 (+0.62%)
SGEN : 228.74 (-0.07%)
MYGN : 19.97 (+2.57%)
ILMN : 118.98 (+0.89%)
BNTX : 93.35 (+0.68%)
BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD PR Newswire - Thu Sep 28, 2023

/PRNewswire/ -- A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast...

MYGN : 19.97 (+2.57%)
Advancements in Pancreatic Cancer Treatment: Biotech Innovations and Rising Optimism BayStreet.ca - Tue Sep 19, 2023

USA News Group – According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic cancer increased by 1% from the previous year to 12%. The...

ONCY : 1.1800 (+0.85%)
ONC.TO : 1.61 (+0.62%)
SGEN : 228.74 (-0.07%)
MYGN : 19.97 (+2.57%)
ILMN : 118.98 (+0.89%)
BNTX : 93.35 (+0.68%)
Myriad: Q2 Earnings Snapshot AP - Thu Aug 3, 2023

Myriad: Q2 Earnings Snapshot

MYGN : 19.97 (+2.57%)
Wall Street - shutterstock_1321462394
Stock Index Futures Move Lower as U.S. Debt Ceiling Uncertainty Weighs on Sentiment, PMI Data in Focus Barchart - Tue May 23, 2023

June S&P 500 futures (ESM23) are down -0.14%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.02% this morning as the U.S. debt ceiling impasse kept risk sentiment fragile, while market participants...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
PACW : 7.54 (-2.71%)
NKE : 93.36 (+1.31%)
BAER.Z.IX : 52.540 (+1.31%)
MYGN : 19.97 (+2.57%)
LFCR : 6.66 (+4.23%)
MVST : 0.4319 (+12.30%)
GH : 19.10 (+1.17%)
QTRX : 16.80 (-1.29%)
Author
Exact Sciences Serves Investors Exactly What They Wished For MarketBeat - Mon May 15, 2023

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The

EXAS : 63.35 (+2.06%)
LH : 201.04 (-0.14%)
MYGN : 19.97 (+2.57%)
DGX : 135.64 (-1.27%)
Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View Zacks - Thu May 4, 2023

Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.

MYGN : 19.97 (+2.57%)
JNJ : 148.58 (-0.46%)
ISRG : 383.05 (+0.44%)
EW : 85.09 (-0.19%)

Barchart Exclusives

After Its Historic Dividend Cut, Is 3M Stock Still Worth Buying? Barchart - Mon May 6, 6:30PM CDT
3M stock is a Dividend King no more, as the company slashed its payout following the Solventum spinoff. Is the stock still a buy for investors seeking passive income? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot